New Long-Acting anesthetic could mean fewer pain shots after surgery

NCT ID NCT07717086

Not yet recruiting Symptom relief Sponsor: Fruithy Holdings Limited Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This early-stage trial tests a new form of the common anesthetic bupivacaine, called HYR-PB21, designed to provide longer pain relief after surgery. Healthy adults receive a single injection of HYR-PB21 at one of three doses or a standard bupivacaine shot. Researchers measure how the drug moves through the body and check for side effects to see if this longer-lasting version is safe enough for further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a longer-acting form of the anesthetic bupivacaine called HYR-PB21 (bupivacaine pamoate)
What this could lead to: If successful, this could lead to a longer-lasting painkiller that reduces the need for repeat injections after surgery.
What could go wrong: This is an early Phase 1 trial in only 28 healthy people, so it is too soon to know if it works or is safe for patients. The drug may not last longer or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTOPERATIVE ANALGESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTOPERATIVE ANALGESIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.